## WHAT IS CLAIMED IS:

A method for the treatment of dry eye and other disorders requiring the
wetting of the eye which comprises topically administering to the eye of
a mammal a composition comprising a pharmaceutically acceptable
carrier and a pharmaceutically effective amount of a compound
formula (I)

$$Z^{1} \longrightarrow Y - A \longrightarrow N - X \longrightarrow N - A^{2} \longrightarrow R^{1}$$

$$Z^{2} \longrightarrow X \longrightarrow N - A^{2} \longrightarrow R^{1}$$

**(l)** 

wherein:

 $Z^1$ ,  $Z^2$  independently = H, F, Br, Cl, F, or  $C_{1-3}$  alkyl;

 $Y = CH-(CH2)_n$  or CH-O;

n = 0-3;

A = CH or N, provided that when Y = CH-O then A = CH;

 $A^2 = CH \text{ or } N;$ 

 $X = (CH2)_{n'}Y^2$  or  $(CH2)_{n'}Y^3(CH2)_{n'}Y^2$ ;

 $X^2 = H$ ,  $OR^5$ ,  $C_{1-6}$  alkyl,  $C(O)OR^6$ , or  $C(O)N(R^7)H$ ;

n' = 2-6;

n'' = 2-4;

 $Y^2 = O, S, or NH$ 

 $Y^3 = O \text{ or } S$ :

 $R^1 = H$ , or  $(C(R^3)(R^4))X^2$ ; and

 $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  independently = H or  $C_{1-6}$  alkyl.

25

10

2. The method of Claim 1 wherein

$$Z^{1}$$
,  $Z^{2} = H$ ;  
 $Y = CH-O$ ;  
 $A = CH$ ;  
 $X = (CH2)_{n} \cdot Y^{2}$ ;  
 $X^{2} = H \text{ or } C(O)OR^{6}$ ;  
 $N' = 2-4$ ;  
 $Y^{2} = O \text{ or } NH$ ; and  
 $R^{2}$ ,  $R^{3}$ ,  $R^{4}$ ,  $R^{6}$  independently = H or  $C_{1-4}$  alkyl.

3. The method of Claim 2 wherein

10

15

20

25

30

$$A^2 = CH$$
;  
 $R^1 = (C(R^3)(R^4))X^2$   
 $R^2$ ,  $R^6$  independently = H or  $C_{1-4}$  alkyl; and  
 $R^3$ ,  $R^4$  independently= H or methyl.

- 4. The method of Claim 1 wherein the compound of formula (I) is selected from the group consisting of
  - 6-[3-[4-(diphenylmethoxy)piperidino]propylamino][1,2,4]triazolol[1,5,b]-pyridazine;
    - 6-[3-[4-(diphenylmethoxy)piperidino]propylamino]-2-methyl[1,2,4]-triazolo[1,5,b]pyridazine;
    - 2-[6-[3-[4-(diphenylmethoxy)piperidino]propylamino]imidazo[1,2,b]-pyridazin-2-yl]-2-methylpropionic acid;
    - 2-[6-[3-[4-(diphenylmethoxy)piperidino]propylamino]imidazo[1,2,b]-pyridazin-2-yl]-2-methylpropionic acid dihydrate; and
    - 2-[6-[3-[4-(diphenylmethoxy)piperidino]propoxy]imidazo[1,2,b]pyridazin-2-yl]-2-methylpropionic acid.

- 5. The method of Claim 1 wherein the pharmaceutically effective amount of the compound of formula (I) in the composition is 0.001 1.0% (w/w).
- 6. The method of Claim 1 wherein the dry eye and other disorders requiring the wetting of the eye is symptoms of dry eye associated with refractive surgery.